ClinicalTrials.gg
CompletedNCT05432479PIXARUpdated Sep 25, 2026

Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief

An interventional study of Probiotic and Placebo in Infantile Colic, sponsored by The Archer-Daniels-Midland Company. Completed at 2 sites in 2 countries. Open to participants aged 3 Weeks to 12 Weeks. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by The Archer-Daniels-Midland Company · Not applicable, Interventional, and Treatment

Updated Sep 25, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
3 Weeks to 12 Weeks
Sex
All
01

Study summary

This study evaluates the efficacy of single strain probiotic administered in a form of a sachet in the treatment of infant colic in infants 3-12 weeks old.

02

Conditions studied

  • Infantile Colic

Browse trials for

Keywords

  • probiotic
  • Bifidobacterium
  • colic
  • cry
03

In context

Colic

127 studies on the registry are indexed under Colic; 18 are open to participants now.

This study's enrollment of 101 is above the median of 76 across 110 interventional studies indexed under Colic.

Browse Colic studies →

Lead sponsor

The Archer-Daniels-Midland Company is the lead sponsor of 19 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Weeks to 12 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gestational age of minimum 37 weeks.
  • Birthweight of minimum 2500 g (5.5 lb.).
  • Age of greater than 3 weeks and less than 12 weeks at enrolment.
  • Confirmed Infantile colic defined as: parental report of crying and/or fussing ≥3 hours/day for ≥3 days/week, confirmed prior to enrolment with an infant behaviour diary recording >3 hours of crying in a 24-hour period (eDiary App completed daily during run-in period \& for duration of study).
  • Participant form signed by parent or legal guardian.
  • Infant is considered healthy following physical exam.
  • Parents/Caregivers are willing to comply with the trial procedures, and the mother of the infant can attend all three trial visits

Exclusion criteria

Exclusion Criteria:

  • Use of antibiotics by the infant within 2-weeks prior to the screening visit or during the run-in period of the trial.
  • Use of probiotic supplements from child's birth to enrolment (this includes infant formulas containing probiotics).
  • Need for hospitalization (defined as readmission to a hospital ward after initial discharge following delivery).
  • Congenital disorders that, in the opinion of the investigator, would impact the gastrointestinal tract.
  • Failure to thrive.
  • Known lactose or gluten intolerance.
  • Known allergy to cow's milk proteins, fish, or any of the substances of the trial product or placebo.
  • Known other causes for abdominal pain (e.g., pyloric stenosis).
  • Participation in any other interventional clinical study.
  • Immuno-compromised participant or participant with other severe chronic disorder.
  • Use of probiotic supplements by breastfeeding mother from child's birth to enrolment.
  • Use of antibiotics by breastfeeding mother within 2-weeks prior to the screening visit or during the run-in period of the trial.
  • Any Participant/Parent/Caregiver who is an employee of the site or an Atlantia Clinical Trials employee or their close family member or a member of their household.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Active

    Arm receiving investigation product (probiotic)

    Dietary Supplement: Probiotic

  • Placebo comparator
    Placebo

    Arm receiving placebo

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementProbiotic

    Single strain probiotic in a form of a sachets with a daily dose of 1.0E+9 Colony Forming Unit (CFU) per day for 4 weeks

  • Dietary supplementPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change in cry and fuss time

    eDiary parent reported cry and fuss time

    Time frame: Day 0, Day 28

Secondary outcomes

  1. Change in cry and fuss time

    eDiary parent reported cry and fuss time

    Time frame: Day 0, Day 7

  2. Resolution of colic symptoms

    Reduction of cry and fuss time (parent reported) greater than 90% comparing to baseline

    Time frame: Day 0, Day 28

  3. Change in cry and fuss time bouts

    eDiary parent reported cry and fuss bouts

    Time frame: Day 0, Day 7, Day 28

  4. Change in sleeping time

    eDiary parent reported sleep time

    Time frame: Day 0, Day 7, Day 28

  5. Change in the use of rescue medications

    Change in the proportion of participants needing to use rescue medications between the study arms

    Time frame: Day 0, Day 28

Other outcomes

  1. Change in maternal quality of life and mental health

    Change in maternal QoL using WHO QOL/BREF (improvement marked by increase in the total score)

    Time frame: Day 0, Day 28

  2. Change in maternal quality of life and mental health

    Change in maternal QoL using MAPP/QoL (improvement marked by increase in the total score)

    Time frame: Day 0, Day 28

  3. Resolution of colic symptoms

    Reduction of cry and fuss time (parent reported) greater than 50% comparing to baseline

    Time frame: Day 0, Day 28

  4. Change in the use of rescue medication drops

    Change in the number of rescue medication drops used between the study arms

    Time frame: Day 0, Day 7, Day 28

  5. Change in duration of daily crying and fussing episodes

    Change in mean duration per crying and fussing episode per day

    Time frame: Day 0, Day 7, Day 28

  6. Changes in gut microbiome composition

    Changes in microbiome composition as measured by changes in alpha and beta diversity of the gut microbiome throughout the study as compared to placebo and baseline

    Time frame: Day 0, Day 28

  7. Change in fecal calprotectin concentration

    Changes in fecal calprotectin concentration throughout the study as compared to placebo and baseline

    Time frame: Day 0, Day 28

  8. Adverse Events (AEs)

    Reports of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From enrolment to Day 35

  9. Change in vital signs

    Changes in vital sign measurements (heart rate \[bpm\] and body temperature \[°F\]) collected during the study will be summarised by treatment group

    Time frame: Day 0, Day 28

07

Study locations

2 sites
  • Atlantia Food Clinical Trials
    Chicago, Illinois 60611, United States
  • Pulse Multispeciality Hospital,
    Pune, Maharashtra Pune 411 041, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Apr 2026, 42 months.

Of 44 interventional studies with no phase under Colic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 42 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion May 2026 → Apr 2026 and completion May 2026 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2022
First posted
Jun 27, 2022
StartActual
Sep 30, 2022
Primary completionActual
Apr 15, 2026was May 2026
CompletionActual
Apr 15, 2026was May 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 25, 2026
Primary completion
May 2026→Apr 15, 2026 (actual)
Sep 25, 2026
Study completion
May 2026→Apr 15, 2026 (actual)
Sep 25, 2026
Enrollment
80 (estimated)→101 (actual)
Sep 25, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameChange in cry and fuss timeDay 0 , Day 28 → Day 0, Day 28
Sep 25, 2026
Secondary outcomes
2 time frame changed, 8 added, 1 description edited
What changed in the outcomes
  • AddedChange in cry and fuss timeTime frame: Day 0, Day 7
  • Time frameChange in cry and fuss time boutsDay 0, Day 28 → Day 0, Day 7, Day 28
  • Time frameChange in sleeping timeDay 0 Day 28 → Day 0, Day 7, Day 28
  • Addedother outcomeResolution of colic symptomsTime frame: Day 0, Day 28
  • Addedother outcomeChange in the use of rescue medication dropsTime frame: Day 0, Day 7, Day 28
  • Addedother outcomeChange in duration of daily crying and fussing episodesTime frame: Day 0, Day 7, Day 28
  • Addedother outcomeChanges in gut microbiome compositionTime frame: Day 0, Day 28
  • Addedother outcomeChange in fecal calprotectin concentrationTime frame: Day 0, Day 28
  • Addedother outcomeAdverse Events (AEs)Time frame: From enrolment to Day 35
  • Addedother outcomeChange in vital signsTime frame: Day 0, Day 28
  • Descriptionother outcomeChange in maternal quality of life and mental health#2: how it is measured was reworded
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Recruiting→Completed
    Primary completion May 2026→Apr 15, 2026 (now actual)
    Study completion May 2026→Apr 15, 2026 (now actual)
    Enrollment 80 (estimated)→101 (actual)
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameChange in cry and fuss timeDay 0 , Day 28 → Day 0, Day 28
    Secondary outcomes 2 time frame changed, 8 added, 1 description edited
    What changed in the outcomes
    • AddedChange in cry and fuss timeTime frame: Day 0, Day 7
    • Time frameChange in cry and fuss time boutsDay 0, Day 28 → Day 0, Day 7, Day 28
    • Time frameChange in sleeping timeDay 0 Day 28 → Day 0, Day 7, Day 28
    • Addedother outcomeResolution of colic symptomsTime frame: Day 0, Day 28
    • Addedother outcomeChange in the use of rescue medication dropsTime frame: Day 0, Day 7, Day 28
    • Addedother outcomeChange in duration of daily crying and fussing episodesTime frame: Day 0, Day 7, Day 28
    • Addedother outcomeChanges in gut microbiome compositionTime frame: Day 0, Day 28
    • Addedother outcomeChange in fecal calprotectin concentrationTime frame: Day 0, Day 28
    • Addedother outcomeAdverse Events (AEs)Time frame: From enrolment to Day 35
    • Addedother outcomeChange in vital signsTime frame: Day 0, Day 28
    • Descriptionother outcomeChange in maternal quality of life and mental health#2: how it is measured was reworded
    + 5 other changes: index terms, verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05432479
Lead sponsor
The Archer-Daniels-Midland Company
Collaborators
Atlantia Food Clinical Trials, Vedic Lifesciences Pvt. Ltd.
Responsible party
Sponsor
First posted
Jun 27, 2022
Start date
Sep 30, 2022
Primary completion
Apr 15, 2026
Completion
Apr 15, 2026
Last update
Sep 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion